Compare Abbott India with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs VENUS REMEDIES - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA VENUS REMEDIES ABBOTT INDIA/
VENUS REMEDIES
 
P/E (TTM) x 47.6 -1.3 - View Chart
P/BV x 13.6 0.1 15,527.6% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 ABBOTT INDIA   VENUS REMEDIES
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
VENUS REMEDIES
Mar-18
ABBOTT INDIA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs6,110126 4,853.1%   
Low Rs3,99661 6,540.1%   
Sales per share (Unadj.) Rs1,552.2301.8 514.3%  
Earnings per share (Unadj.) Rs188.8-24.9 -759.2%  
Cash flow per share (Unadj.) Rs196.42.5 7,719.3%  
Dividends per share (Unadj.) Rs55.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs796.6293.3 271.6%  
Shares outstanding (eoy) m21.2512.34 172.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.30.3 1,050.7%   
Avg P/E ratio x26.8-3.8 -711.9%  
P/CF ratio (eoy) x25.736.7 70.0%  
Price / Book Value ratio x6.30.3 1,989.7%  
Dividend payout %29.10-   
Avg Mkt Cap Rs m107,3761,154 9,306.4%   
No. of employees `0003.30.9 359.1%   
Total wages/salary Rs m3,937393 1,001.5%   
Avg. sales/employee Rs Th9,929.34,026.1 246.6%   
Avg. wages/employee Rs Th1,185.1425.0 278.9%   
Avg. net profit/employee Rs Th1,207.7-331.8 -364.0%   
INCOME DATA
Net Sales Rs m32,9853,724 885.7%  
Other income Rs m1,17023 5,199.6%   
Total revenues Rs m34,1553,747 911.6%   
Gross profit Rs m5,245395 1,328.5%  
Depreciation Rs m162338 47.9%   
Interest Rs m38354 10.8%   
Profit before tax Rs m6,215-275 -2,257.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,20332 6,970.6%   
Profit after tax Rs m4,012-307 -1,307.3%  
Gross profit margin %15.910.6 150.0%  
Effective tax rate %35.4-11.5 -308.8%   
Net profit margin %12.2-8.2 -147.6%  
BALANCE SHEET DATA
Current assets Rs m22,6552,638 858.9%   
Current liabilities Rs m6,6812,305 289.9%   
Net working cap to sales %48.48.9 541.5%  
Current ratio x3.41.1 296.3%  
Inventory Days Days65135 47.8%  
Debtors Days Days2946 62.9%  
Net fixed assets Rs m8354,871 17.2%   
Share capital Rs m213123 172.2%   
"Free" reserves Rs m16,7153,496 478.2%   
Net worth Rs m16,9283,619 467.7%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m24,1627,509 321.8%  
Interest coverage x163.70.2 73,412.4%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.40.5 275.2%   
Return on assets %16.80.6 2,655.4%  
Return on equity %23.7-8.5 -279.5%  
Return on capital %36.91.6 2,334.9%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m3690-   
Fx outflow Rs m3,807517 737.0%   
Net fx Rs m-3,438-517 665.6%   
CASH FLOW
From Operations Rs m1,527514 296.9%  
From Investments Rs m-2,148-123 1,745.2%  
From Financial Activity Rs m-1,024-387 264.6%  
Net Cashflow Rs m-1,6464 -39,181.0%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 0.2 4,388.9%  
FIIs % 0.1 0.6 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 66.4 25.8%  
Shareholders   18,270 20,121 90.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   PFIZER  GSK PHARMA  PLETHICO PHARMA  WYETH LTD  TORRENT PHARMA  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Realty and Telecom Stocks Drag(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is flat while the Hang Seng is down 0.9%.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY19); Net Profit Up 13.1% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 13.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.0% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY19); Net Profit Up 1.4% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 1.4% YoY). Sales on the other hand came in at Rs 9 bn (up 7.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Oct 23, 2019 10:53 AM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS